Bosentan treatment for Raynauds phenomenon and skin @entity82 in @entity1 with Systemic Sclerosis and XXXX : an open-label, observational, retrospective study.

@entity1 @entity82 @entity12584 @entity2232 @entity72272 @entity1066 @entity120 @entity2631 @entity6391 @entity7087
Raynaud?s phenomenon ( @entity6391 ) and cutaneous @entity82 are the distinctive manifestations of @entity2631 , in which @entity2232 plays a fundamental pathogenetic role. Bosentan, an @entity2232 receptor antagonist used for the treatment of @entity120 , retards the beginning of new @entity1066 (DU). This open-label, observational, retrospective study verified the effect of @entity12584 on @entity6391 and skin @entity82 in sclerodermic outpatients affected by @entity120 without DU. Fourteen subjects (13 @entity1 , 1 @entity1 ; mean age 60    7.5 years; ten with limited and four with @entity7087 ) were observed at baseline (T0) and after four (T1), twelve (T2), twenty-four (T3) and forty-eight (T4) weeks during treatment with Bosentan. They were evaluated for daily quantity and duration of @entity6391 attacks and skin thickness (using modified Rodnan total skin score, @entity72272 ). Videocapillaroscopic evaluation was performed at T0 and T4. Bosentan decreased significantly the number and duration of @entity6391 attacks, beginning at T2 (p<0.05). Videocapillaroscopy showed significant improvement of microcirculatory patterns at T4 (p<0.05). @entity72272 decreased throughout the study, reaching the statistical significance at T3 and T4 (p<0.01) in the whole cohort. The present data suggest that Bosentan is effective in stabilizing the microcirculation involvement and in improving skin @entity82 irrespective of @entity2631 patterns.
